Your browser doesn't support javascript.
loading
OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data.
Kass-Hout, Taha A; Xu, Zhiheng; Mohebbi, Matthew; Nelsen, Hans; Baker, Adam; Levine, Jonathan; Johanson, Elaine; Bright, Roselie A.
Afiliação
  • Kass-Hout TA; U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Xu Z; U.S. Food and Drug Administration, Silver Spring, MD, USA zhiheng.xu@fda.hhs.gov.
  • Mohebbi M; Iodine, Inc. 34 Clyde Street, San Francisco, CA 94107, USA.
  • Nelsen H; Iodine, Inc. 34 Clyde Street, San Francisco, CA 94107, USA.
  • Baker A; Iodine, Inc. 34 Clyde Street, San Francisco, CA 94107, USA.
  • Levine J; U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Johanson E; U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Bright RA; U.S. Food and Drug Administration, Silver Spring, MD, USA.
J Am Med Inform Assoc ; 23(3): 596-600, 2016 05.
Article em En | MEDLINE | ID: mdl-26644398
ABSTRACT

OBJECTIVE:

The objective of openFDA is to facilitate access and use of big important Food and Drug Administration public datasets by developers, researchers, and the public through harmonization of data across disparate FDA datasets provided via application programming interfaces (APIs). MATERIALS AND

METHODS:

Using cutting-edge technologies deployed on FDA's new public cloud computing infrastructure, openFDA provides open data for easier, faster (over 300 requests per second per process), and better access to FDA datasets; open source code and documentation shared on GitHub for open community contributions of examples, apps and ideas; and infrastructure that can be adopted for other public health big data challenges.

RESULTS:

Since its launch on June 2, 2014, openFDA has developed four APIs for drug and device adverse events, recall information for all FDA-regulated products, and drug labeling. There have been more than 20 million API calls (more than half from outside the United States), 6000 registered users, 20,000 connected Internet Protocol addresses, and dozens of new software (mobile or web) apps developed. A case study demonstrates a use of openFDA data to understand an apparent association of a drug with an adverse event.

CONCLUSION:

With easier and faster access to these datasets, consumers worldwide can learn more about FDA-regulated products.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: United States Food and Drug Administration / Software / Sistemas de Notificação de Reações Adversas a Medicamentos / Conjuntos de Dados como Assunto País/Região como assunto: America do norte Idioma: En Revista: J Am Med Inform Assoc Assunto da revista: INFORMATICA MEDICA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: United States Food and Drug Administration / Software / Sistemas de Notificação de Reações Adversas a Medicamentos / Conjuntos de Dados como Assunto País/Região como assunto: America do norte Idioma: En Revista: J Am Med Inform Assoc Assunto da revista: INFORMATICA MEDICA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos